During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied
by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly
(ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and
poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers
are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of
drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment
of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates
have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by
FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements
in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Rights & PermissionsPrintExport